We are excited to welcome Ben Maurey to Reglagene as our commercial-focused advisor on our Advisory Board. Ben comes to Reglagene after 8 years in the oncology space with a wide variety of roles and responsibilities. He started his career off in strategic consulting and eventually ran the Market Strategy Team at Vaniam Group, with his team focusing on early asset and market access strategy. Most recently, Ben ran market insights for early stage assets at Seagen and continued with the company after they were acquired by Pfizer. In addition to his commercial consulting and industry experience Ben has assisted with clinical/medical affairs strategy and was a Venture Partner at The Cancer Fund.

Thinking Small has lead to the biggest breakthrough. Yesterday, Reglagene's CEO Richard Austin presented at the BIO International Convention in San Diego. Here, he discussed how Reglagene's therapy has the unique ability to cross through the blood-brain barrier and fight brain cancer. Reach out to learn more!

Thank you Angel Capital Association for selecting Reglagene as one of your Innovation Funders Showcase companies! CEO Richard Austin captivated the audience in Columbus, Ohio with a presentation on how "Thinking Small" has changed the way we think about treating brain cancer.

Thrilled to have been part of Destination Startup hosted by Venture Partners at CU Boulder! Reglagene's CEO, Richard Austin, captivated a full room at 1:00 PM MDT with an exciting presentation focused on business and scientific milestones. A big thank you to Tech Launch Arizona for the invitation and to Stephen Miller for coordinating this fantastic event!

Reglagene's lead product, RGN6024, was accepted into TMC's Accelerator for Cancer Therapeutics. Find the full announcement below or on the EIN Presswire.

Pitching to a full house during Reglagene's presentation at BIO CEO & Investor Conference, in Times Square, New York City!

Last week, Teri Suzuki, Lilian Patrón, and Michael Abrahamson participated in the 16th Annual BIO5/BIOSA Student Industry Networking Event.

Reglagene's lead product, RGN6024, has received an exclusive orphan drug designation from the FDA. Read the full announcement here, or on the EIN Presswire.